louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00837213: Comparative Efficacy and Safety of Benzoyl Peroxide Used in Combination With Clindamycin vs. Benzoyl Peroxide Used in Combination With Clindamycin and Doxycycline in the Treatment of Moderate Acne
Official title: Comparative Efficacy and Safety of Benzoyl Peroxide Used in Combination With Clindamycin vs. Benzoyl Peroxide Used in Combination With Clindamycin and Doxycycline in the Treatment of Moderate Acne
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Acne
Keywords: Acne
Lead sponsor: GlaxoSmithKline
Sponsor class: INDUSTRY
Collaborators: name: GlaxoSmithKline
First posted: 2009-02-05
Enrollment: 33
Sex: ALL
Minimum age (years): 16
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To compare the efficacy and safety of Benzoyl peroxide used in combination with clindamycin vs. Benzoyl peroxide used in combination with clindamycin and doxycycline in the treatment of moderate acne

Detailed description: To compare the efficacy and safety of Benzoyl peroxide used in combination with clindamycin vs. Benzoyl peroxide used in combination with clindamycin and doxycycline once daily in the treatment of moderate acne

Eligibility criteria: Inclusion Criteria:

* Male or female subjects with acne vulgaris . Able to understand the requirements of the study and sign informed consent/HIPAA authorization forms.

Exclusion Criteria:

* Known hypersensitivity to any of the components of the study drugs or used of prohibited medications or any medical condition that contraindicate the subject's participation in the clinical study

Primary outcomes:
measure: Percent Change in Inflammatory Acne Lesions From Baseline to Week 16
timeFrame: Baseline, Week 16
measure: Percent (%) Change in Non-inflammatory Acne Lesions From Baseline to Week 16.
timeFrame: Baseline, Week 16
measure: Percent Change in Total Acne Lesion Counts From Baseline to Week 16
timeFrame: Baseline, Week 16
measure: Change in Investigator Global Assessment (IGA)
timeFrame: Baseline, Weeks 4, 8,12, and 16
Secondary outcomes:
measure: Percent (%) Change in Inflammatory Lesion Counts (Chest and Back) From Baseline to Week 12
timeFrame: Baseline, Week 12
measure: Percent Change in Non-inflammatory Lesions (Chest and Back) From Baseline to Week 12
timeFrame: Baseline, Week 12
measure: Percent Change in Total Lesions (Chest and Back) From Baseline to Week 12
timeFrame: Week 12
measure: Percentage of Particpants With IGA Score at Week 16
timeFrame: Baseline, Week 16
Other outcomes:
Locations:
city: Fremont
country: United States
facility: Center for Dermatology, Cosmetic and Laser Surgery
state: California
city: Las Vegas
country: United States
facility: Las Vegas Skin & Cancer Clinic
state: Nevada
Study officials:
affiliation: GlaxoSmithKline
name: GSK Clinical Trials
role: STUDY_DIRECTOR
References:
Clinical trial NCT00453713: Race, Ethnicity, and Diffuse Parenchymal Lung Disease
Official title: Determinants of Outcome in Diffuse Parenchymal Lung Disease
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Idiopathic Pulmonary Fibrosis
Interstitial Lung Disease
Diffuse Parenchymal Lung Disease
Keywords: Idiopathic pulmonary fibrosis
Interstitial lung disease
Diffuse parenchymal lung disease
Health disparities
Lead sponsor: Columbia University
Sponsor class: OTHER
Collaborators: name: National Heart, Lung, and Blood Institute (NHLBI)
First posted: 2007-03-29
Enrollment: 565
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Diffuse parenchymal lung disease

Brief summary: The purpose of this study is to identify factors that contribute to higher mortality rates among blacks and Hispanics with diffuse parenchymal lung disease.

Detailed description: It is well known that both socioeconomic and biological factors may contribute to race- and ethnicity-based health disparities. Black and Hispanic Americans have worse access to healthcare services and tend to receive care from physicians who cannot themselves access the same services for their patients that physicians who care for white patients can. These factors may play important roles in the development and maintenance of health disparities. In addition, biological differences may contribute to disparities. We propose to identify factors that explain survival disparities in a group of lung diseases called diffuse parenchymal lung diseases (DPLDs), including a severe form of DPLD called idiopathic pulmonary fibrosis (IPF). We will follow patients with DPLD at our center and measure both social and biological factors to try to identify the factors that lead to survival disparities between races. Results of this study will be used to design clinical trials aimed at reducing these disparities.

Eligibility criteria: Inclusion Criteria:

* Diagnosis of IPF or other DPLD according to ATS criteria
* Signed informed consent

Exclusion Criteria:

* None

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: New York
country: United States
facility: Columbia University Medical Center
state: New York
Study officials:
affiliation: Columbia University
name: David J Lederer, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02004613: Ancillary Effects of Dexmedetomidine Sedation After Cardiac Surgery
Official title: Ancillary Effects of Dexmedetomidine Sedation After Cardiac Surgery
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Heart Disease
Lead sponsor: The Cleveland Clinic
Sponsor class: OTHER
Collaborators: name: Hospira, now a wholly owned subsidiary of Pfizer
First posted: 2013-12-09
Enrollment: 798
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Ancillary Effects of Dexmedetomidine Sedation After Cardiac Surgery

Detailed description: The investigator goal is to evaluate the effects of intraoperative and postoperative dexmedetomidine sedation (versus placebo after cardiac surgery.

Eligibility criteria: Inclusion Criteria:

1. 18-85 years old;
2. Scheduled for cardiac surgery with bypass (CABG, valve, or combined);
3. Able to provide a written informed consent;
4. Hemodynamically stable (heart rate\>= 55).

Exclusion Criteria:

1. Sick sinus syndrome or Wolff-Parkinson-White syndrome
2. Atrio-ventricular block
3. Hypersensitivity or known allergy to dexmedetomidine
4. Hepatic disease, e.g. twice the normal level of liver enzymes
5. Atrial fibrillation within 1 preoperative month;
6. Permanent pacemaker;
7. Use of amiodarone or dexmedetomidine within the last 30 days;
8. Patients with an ejection fraction under 30% or who had severe heart failure
9. Myocardial infarction in the previ¬ous 7 days;
10. Body mass index =\< 40 (BMI= mass (kg) / height (m)2);
11. Those taking clonidine within last 48 hours.

Primary outcomes:
measure: Number of Patients With Atrial Arrhythmia
timeFrame: From the end of surgery to postoperative day 5
measure: Number of Patients With Delirium
timeFrame: From the end of surgery to postoperative day 5
Secondary outcomes:
measure: Number of Patients With Acute Kidney Injury
timeFrame: From the end of surgery to postoperative day 5
measure: Number of Patients With Incisional Pain
timeFrame: 90 days after surgery
Other outcomes:
Locations:
city: Cleveland
country: United States
facility: Cleveland Clinic Main
state: Ohio
Study officials:
affiliation: Staff member
name: Alparslan Turan, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Turan A, Duncan A, Leung S, Karimi N, Fang J, Mao G, Hargrave J, Gillinov M, Trombetta C, Ayad S, Hassan M, Feider A, Howard-Quijano K, Ruetzler K, Sessler DI; DECADE Study Group. Dexmedetomidine for reduction of atrial fibrillation and delirium after cardiac surgery (DECADE): a randomised placebo-controlled trial. Lancet. 2020 Jul 18;396(10245):177-185. doi: 10.1016/S0140-6736(20)30631-0.
Clinical trial NCT05622513: Phthalate Esters and Childhood Obesity
Official title: the Association Between Phthalate Esters and Childhood Obesity
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Childhood Obesity
Lead sponsor: Shenzhen Center for Disease Control and Prevention
Sponsor class: OTHER_GOV
First posted: 2022-11-18
Enrollment: 480
Sex: ALL
Minimum age (years): 6
Maximum age (years): 8
Standard ages: CHILD
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Students aged 6-8 years from monitoring schools in Shenzhen, China.

Brief summary: Phthalate esters have been considered closely related with childhood obesity, but the existing studies revealed inconsistent results. This study was desigened to investigate the association between phthalate esters and childhood obesity in China.

Detailed description: The physical activity, dietary intake and the levels of urine phthalate metabolites of children were detected, and the associations between these 3 factors and childhood obesity were analyzed.

Eligibility criteria: Inclusion Criteria:

* Children who were classified as normal, overweight and obesity based on age, gender and BMI.

Exclusion Criteria:

* The participants who were with endocrine disorders.

Primary outcomes:
measure: the levels of urine phthalate metabolites
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT05687513: Clinical Efficacy and Mechanism of Yisui Granule in Treatment of Low and Medium Risk Myelodysplastic Syndrome Through Demethylation
Official title: Clinical Efficacy and Mechanism of Yisui Granule in Treatment of Low and Medium Risk Myelodysplastic Syndrome Through Demethylation
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: EARLY_PHASE1
Conditions: MDS
Lead sponsor: Dongzhimen Hospital, Beijing
Sponsor class: OTHER
First posted: 2023-01-18
Enrollment: 76
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The goal of this clinical trial is to explore the mechanism of Yisui Granule(YSG) in the treatment of myelodysplastic syndrome(MDS) through demethylation.

Under the same condition of basic western medicine treatment, the treatment group used the same traditional Chinese medicine decoction pieces as YSG, and the control group was given placebo. Through a randomized controlled clinical study, we focused on observing the effects of MDS patients on clinical symptoms (including single symptom), fatigue relief, quality of life, peripheral blood picture, blood transfusion interval and blood transfusion volume, and measured the expression of DNMTs, the expression and methylation level of Wnt3a、β-catenin、SFRP and other indicators, as well as cytokines, were used to explore the mechanism of YSG in the treatment of MDS through demethylation.


Eligibility criteria: A. Diagnosed as myelodysplastic syndrome, IPSS score 0-1; B. It meets the syndrome standard of "deficiency of both qi and yin, internal resistance of blood stasis"; C. Newly diagnosed cases or no application of other Chinese and western medicines or treatment schemes in the past month; D. Take the test voluntarily and sign the informed consent form.

Primary outcomes:
measure: Methylation index
timeFrame: 8 weeks
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT03643913: The Effect of Deep Neuromuscular Block and Reversal With Sugammadex on Surgical Conditions and Perioperative Morbidity in Shoulder Surgery Using a Deltopectoral Approach
Official title: The Effect of Deep Neuromuscular Block and Reversal With Sugammadex on Surgical Conditions and Perioperative Morbidity in Shoulder Surgery Using a Deltopectoral Approach
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Shoulder Pain
Anesthesia
Lead sponsor: Universitaire Ziekenhuizen KU Leuven
Sponsor class: OTHER
Collaborators: name: MSD Belgium BVBA
First posted: 2018-08-23
Enrollment: 52
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The study evaluates wether deep neuromuscular block during entire surgical procedure to the gleno-humeral joint or the proximal humerus using a deltoideo-pectoral approach results in less muscular damage to the deltoid muscle and therefore less post-operative pain and an earlier functional recovery..


Eligibility criteria: Inclusion Criteria:

• Adult patient undergoing elective or semi-elective surgery to the gleno-humeral joint or the proximal humerus using a deltoideo-pectoral approach

Exclusion Criteria:

* Inability to consent because of mental status
* Open injuries involving the deltoid muscle
* Previous open surgery on the shoulder joint.
* American Society of Anaesthesiologists (ASA) physical status \>II
* Age \<18 or \>85 year old
* Body mass index (BMI) \<18.5 or \>35 kg/m2
* Renal insufficiency (glomerular filtration rate \<40 ml/min)
* Impaired liver function (hepatic cirrhosis, cholestatic jaundice)
* Neuromuscular disease
* Pregnancy
* Breastfeeding
* Predicted difficult airway
* Patients receiving medications known to interact with neuromuscular blocking agents
* Allergy to any drug included in the anesthetic protocol

Primary outcomes:
measure: Modified Leiden score
timeFrame: 1 Day of surgery
measure: Visual analogue scale (VAS)
timeFrame: Day 3 post-operative at 14 o' clock
Secondary outcomes:
measure: Muscular damage
timeFrame: 1 Day of surgery
measure: Muscular damage
timeFrame: 1 year after inclusion
measure: VAS
timeFrame: The scoring will be done at 8-14 and 20 o'clock on days 1-3-5 post-operative and once a day from day 5 to day 30 post-operative.
measure: Analgesic needs
timeFrame: Up to 5 days post-operative
measure: Analgesic needs
timeFrame: From hospital discharge to 30 days post-operative
measure: Length of stay at post-anesthesia care unit (PACU)
timeFrame: 1 Day of surgery
measure: Length of surgery
timeFrame: intraoperative
measure: Length of stay
timeFrame: from day 3 up to 3 weeks after surgery
measure: Evaluation of dry catheter technique
timeFrame: 1 Day of surgery
Other outcomes:
Locations:
city: Leuven
country: Belgium
facility: University Hospitals Leuven
state: Vlaams-Brabant
Study officials:
affiliation: Universitaire Ziekenhuizen KU Leuven
name: Harm Hoekstra, Prof. Dr.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00998413: Weight-reduction Intervention in Asthmatic Children With Overweight/Obesity
Official title: Secondary Prevention of Asthma in Overweight/Obese Children by a Combined Dietary-behavioural-physical Activity Intervention
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Asthma
Overweight
Obesity
Keywords: asthma
overweight
obesity
children
Lead sponsor: Maastricht University Medical Center
Sponsor class: OTHER
Collaborators: name: The Netherlands Asthma Foundation
First posted: 2009-10-20
Enrollment: 87
Sex: ALL
Minimum age (years): 6
Maximum age (years): 16
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to determine the efficacy of a multifactorial intervention with weight reduction, behavioural therapy, and physical exercise on the severity and control of asthma in obese children.


Eligibility criteria: Inclusion Criteria:

* Children aged 6-16 years
* BMI in the overweight/obesity range according to data of Cole et al.
* Asthma diagnosis

Exclusion Criteria:

* Children with a normal weight according to data of Cole et al.
* Children without any provable asthmatic complaints
* Congenital malformations of the airways or other chronic lung diseases like cystic fibrosis (CF)
* Mental retardation or syndromes
* Heart disease

Primary outcomes:
measure: Forced Expiratory Volume in the first second (FEV1 %) predicted value
timeFrame: 2 years
Secondary outcomes:
measure: Airway inflammation
timeFrame: 2 years
measure: Symptom-free days, exacerbations
timeFrame: 2 years
measure: Need for beta-2 agonists/anti-inflammatory medication
timeFrame: 2 years
measure: Weight, height, body mass index (BMI)
timeFrame: 2 years
measure: Levels of serum adipokines
timeFrame: 2 years
measure: aerobic capacity
timeFrame: 2 years
Other outcomes:
Locations:
city: Maastricht
country: Netherlands
facility: Maastricht University Medical Centre
state: Limburg
city: Maastricht
country: Netherlands
facility: Maastricht University Medical Centre
state: Limburg
Study officials:
affiliation: Maastricht University Medical Centre
name: Edward Dompeling, PhD, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Maastricht University Medical Centre
name: Kim van de Kant, MSc
role: STUDY_CHAIR
References:
citation: Willeboordse M, van de Kant KDG, Tan FE, Mulkens S, Schellings J, Crijns Y, Ploeg Lv, van Schayck CP, Dompeling E. A Multifactorial Weight Reduction Programme for Children with Overweight and Asthma: A Randomized Controlled Trial. PLoS One. 2016 Jun 13;11(6):e0157158. doi: 10.1371/journal.pone.0157158. eCollection 2016.
citation: Willeboordse M, van de Kant KD, de Laat MN, van Schayck OC, Mulkens S, Dompeling E. Multifactorial intervention for children with asthma and overweight (Mikado): study design of a randomised controlled trial. BMC Public Health. 2013 May 21;13:494. doi: 10.1186/1471-2458-13-494.
Clinical trial NCT04946513: Hip Arthroscopy Improves Muscle Volumes in Patients With Femoroacetabular Impingement Syndrome
Official title: The Influence of Hip Arthroscopy on Postoperative Muscle Volumes in Patients With Femoroacetabular Impingement Syndrome
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Femoroacetabular Impingement Syndrome
Lead sponsor: Peking University Third Hospital
Sponsor class: OTHER
First posted: 2021-07-01
Enrollment: 195
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with femoroacetabular impingement syndrome and underwent hip arthroscopy.

Brief summary: To explore the changes of the muscles around the hip joint after hip arthroscopy for patients with femoral acetabular impingement syndrome.

Detailed description: Retrospectively investigate the influence of hip arthroscopy on the muscle volume around the hip joint, and to provide important information for clinicians to make diagnosis and treatment plan of hip joint disease.

Eligibility criteria: Inclusion Criteria: (1) Age 18-50 years old; (2) Diagnosed femoroacetabular impingement syndrome; (3) Conservative treatment ineffective; (4) complete preoperative and postoperative MRI images; -

Exclusion Criteria: (1) bilateral; (2) revision; (3) osteoarthritis; (4) acetabular dysplasia; (5) history of hip and knee joint disease or surgery; (6) femoral head necrosis; (7) sacroiliac joint disease.

-

Primary outcomes:
measure: Muscle volumes
timeFrame: 1 year after hip arthroscopy
Secondary outcomes:
Other outcomes:
Locations:
city: Beijing
country: China
facility: Peking University Third Hospital
Study officials:
affiliation: Peking University Third Hospital
name: Jian-quan Wang, M.D.
role: STUDY_CHAIR
References:
Clinical trial NCT01846013: Increasing Workplace Physical Activity in Sedentary Office Workers
Official title: Increasing Workplace Physical Activity in Sedentary Office Workers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Sit-Stand Workstations
Keywords: Sit-Stand Workstations
Increase Workplace Physical Activity
Lead sponsor: University of Minnesota
Sponsor class: OTHER
Collaborators: name: Mayo Clinic
First posted: 2013-05-03
Enrollment: 260
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: Purpose:

The purpose of this study is to implement and evaluate a randomized controlled trial in sitting office workers to reduce sitting time through the use of motorized and non-motorized sit/stand workstations as well as a walking intervention.

Hypotheses:

1. Compared to the control group, total physical activity will be higher in the standing and walking intervention groups.
2. The combined standing and walking group will have higher total physical activity than the other three groups.
3. Compared to the control group, the fitness and health outcomes will be improved for the standing and walking groups.


Eligibility criteria: Inclusion Criteria:

* Sedentary adults who use a single computer workstation for the majority of their workday
* Work full time (at least 35 hours per week)
* Must have ability to safely begin a standing and/or walking protocol with no adverse side effects

Exclusion Criteria:

* Musculoskeletal or joint problems
* Severe autoimmune conditions
* Varicose veins that may cause pain
* Women who are pregnant

Primary outcomes:
measure: Total physical activity
timeFrame: 6-months
Secondary outcomes:
measure: Fasting blood glucose
timeFrame: 6-months
Other outcomes:
measure: Total cholesterol
timeFrame: 6-months
measure: Body composition
timeFrame: 6-months
Locations:
city: Minneapolis
country: United States
facility: University of Minnesota
state: Minnesota
city: Saint Paul
country: United States
facility: Fairview Energy Park
state: Minnesota
city: Saint Paul
country: United States
facility: MN Department of Human Services
state: Minnesota
Study officials:
affiliation: University of Minnesota
name: Mark A Pereira, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: University of Minnesota
name: Katie C Carpenter, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: University of Minnesota
name: Amanda R Bonikowske, MA
role: PRINCIPAL_INVESTIGATOR
References: